Oxyphenisatin Acetate

Summary

Oxyphenisatin Acetate (CHEMBL1402684) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 401.4 Da · C24H19NO5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1402684
Name	Oxyphenisatin Acetate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	8269
Molecular formula	C24H19NO5
Molecular weight	401.4
InChIKey	PHPUXYRXPHEJDF-UHFFFAOYSA-N

SMILES: CC(=O)OC1=CC=C(C=C1)C2(C3=CC=CC=C3NC2=O)C4=CC=C(C=C4)OC(=O)C

IUPAC name: [4-[3-(4-acetyloxyphenyl)-2-oxo-1H-indol-3-yl]phenyl] acetate

Also known as: Acetphenolisatin, Isocrin, NSC-117186, NSC-59687, Oxyphenisatin acetate, Oxyphenisatin diacetate, Oxyphenisatine acetate, Veripaque, SID29215359, SID26754500, OXYPHENISATIN ACETATE, SID144205204

Patent coverage: 164 distinct patent families (353 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 320 (91%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Microtubule-associated protein tau.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 3 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
MAPT	5.4	Potency	3981	nM	CHEMBL_ACT_4502707
MAPT	5.15	Potency	7080	nM	CHEMBL_ACT_3972215
MAPT	5.15	Potency	7080	nM	CHEMBL_ACT_4028920

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).